What treatments are available for PNH?
Ravulizumab and eculizumab (trade name: Soliris®), known as complement inhibitors, aim to
prevent the destruction of the red blood cells, improve common symptoms of PNH, and prevent
life-threatening complications.
Complement inhibitors work by sticking to a protein in the blood called C5, which helps stop the red
blood cells from breaking down.
Complement inhibitor Protective protein Less destruction
treatment given directly shields red blood happening to red
into the bloodstream cell from attack blood cell
What were the treatments used in this study?
There were 2 treatment groups in this study: ravulizumab and eculizumab. The treatments were
given by an infusion, which means it was administered directly into the bloodstream via a drip.
A computer selected at random who got ravulizumab and who got eculizumab.
RAVULIZUMAB ECULIZUMAB
Up to 3000* mg infusion for the first dose, 900^ mg infusion once every 2 weeks.
up to 3600* mg on Day 15, and up to
3600* mg once every 8 weeks after that.
Each infusion was around 2 hours. Each infusion was around 35 minutes.
97 patients got ravulizumab infusions. 98 patients got eculizumab infusions.
*Exact dose based on body weight. ^Exact dose not based on body weight.
Protocol, ALXN1210-PNH-302 SPONSOR CONTACT INFORMATION:
Europe, 2016-002026-36 1-888-765-4747
© Certara USA, Inc. 2020. All rights reserved United States, NCT03056040 medinfo@alexion.com 3